Explore the words cloud of the MS4Drug project. It provides you a very rough idea of what is the project "MS4Drug" about.
The following table provides information about the project.
Coordinator |
CHIESI FARMACEUTICI SPA
Organization address contact info |
Coordinator Country | Italy [IT] |
Total cost | 171˙473 € |
EC max contribution | 171˙473 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2018 |
Funding Scheme | MSCA-IF-EF-SE |
Starting year | 2019 |
Duration (year-month-day) | from 2019-07-01 to 2021-06-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | CHIESI FARMACEUTICI SPA | IT (Parma) | coordinator | 171˙473.00 |
Pulmonary Arterial Hypertension (PAH) is a life-threatening condition; even if treated, patients only have a 5-year survival rate of less than 60%. For the treatment of PAH, Chiesi Pharmaceuticals develops Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitors. The aim of this project is to elucidate conformational changes in ROCK in vitro as well as in the cellular environment that are induced by anti-PAH drug candidates, which are currently being tested in preclinical trials at Chiesi Pharmaceuticals. The ROCK interactome will be mapped to gain detailed insights into the molecular mechanisms underlying the signaling pathways of ROCK. We will decipher the effect of anti-PAH drug candidates on the ROCK interactome and elucidate drug-induced conformational changes in ROCK. Identifying novel pharmacological targets modulating specific ROCK/protein interactions will eventually lead to novel drugs for an improved treatment of PAH. This project will integrate, for the first time, in cell cross-lining mass spectrometry (XLMS), in conjunction with hydrogen/deuterium exchange mass spectrometry (HDX-MS), in the drug discovery pipeline of a pharma company. It will be the first application of the XLMS approach in the field of structural biology in Italy. The conformations and interactions of ROCK, derived by in cell XLMS, will allow a systematic validation of in vitro biochemical studies. This project aims to advance the in cell XLMS approach into a routine method for drug discovery on the system-wide level that complements HDX-MS studies using isolated proteins. Novel cross-linking reagent will be developed to bring the XLMS approach to a new level of time-resolved protein interaction studies. As such, the integrated approach described herein opens unmatched and novel perspectives for biotechnological and pharmaceutical companies. The outcome of this project is expected to have a large impact on structural biology and drug discovery in general.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MS4DRUG" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MS4DRUG" are provided by the European Opendata Portal: CORDIS opendata.
Neural mechanisms of crossmodal activity in blind and sighted individuals
Read MoreQuality of Service for the Internet of Things in Smart Cities via Predictive Networks
Read MoreMultiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation
Read More